Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice
(2008) In BMC Cancer 8.- Abstract
- Background: Metastatic prostate cancer is associated with a high morbidity and mortality but the spreading mechanisms are still poorly understood. The aminobisphosphonate alendronate, used to reduce bone loss, has also been shown to inhibit the invasion and migration of prostate cancer cells in vitro. We used a modified orthotopic PC-3 nude mouse tumor model of human prostate cancer to study whether alendronate affects prostate tumor growth and metastasis. Methods: PC-3 cells ( 5 x 105) were implanted in the prostates of nude mice and the mice were treated with alendronate ( 0.5 mg/kg/day in PBS, s.c.) or vehicle for 4 weeks. After sacrifice, the sizes of tumor-bearing prostates were measured and the tumors and prostate-draining regional... (More)
- Background: Metastatic prostate cancer is associated with a high morbidity and mortality but the spreading mechanisms are still poorly understood. The aminobisphosphonate alendronate, used to reduce bone loss, has also been shown to inhibit the invasion and migration of prostate cancer cells in vitro. We used a modified orthotopic PC-3 nude mouse tumor model of human prostate cancer to study whether alendronate affects prostate tumor growth and metastasis. Methods: PC-3 cells ( 5 x 105) were implanted in the prostates of nude mice and the mice were treated with alendronate ( 0.5 mg/kg/day in PBS, s.c.) or vehicle for 4 weeks. After sacrifice, the sizes of tumor-bearing prostates were measured and the tumors and prostate-draining regional iliac and sacral lymph nodes were excised for studies on markers of proliferation, apoptosis, angiogenesis and lymphangiogenesis, using histomorphometry and immunohistochemistry. Results: Tumor occurrence in the prostate was 73% in the alendronate-treated group and 81% in the control group. Mean tumor size ( 218 mm(3), range: 96-485 mm(3), n = 11) in the alendronate-treated mice was 41% of that in the control mice ( 513 mm(3), range: 209 - 1350 mm(3), n = 13) ( p < 0.05). In the iliac and sacral lymph nodes of alendronate-treated mice, the proportion of metastatic area was only about 10% of that in control mice ( p < 0.001). Immunohistochemical staining of tumor sections showed that alendronate treatment caused a marked decrease in the number of CD34-positive endothelial cells in tumors ( p < 0.001) and an increase in that of ISEL positive apoptotic cells in tumors as well as in lymph node metastases ( p < 0.05) compared with those in the vehicle-treated mice. The density of m-LYVE-I-stained lymphatic capillaries was not changed. Conclusion: Our results demonstrate that alendronate treatment opposes growth of orthotopic PC-3 tumors and decreases tumor metastasis to prostate-draining lymph nodes. This effect could be at least partly explained by decreased angiogenesis and increased apoptosis. The results suggest that bisphosphonates have anti-tumoral and anti-invasive effects on primary prostate cancer. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1207346
- author
- Tuomela, Johanna M. ; Valta, Maija P. ; Vaananen, Kalervo and Härkönen, Pirkko LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- BMC Cancer
- volume
- 8
- publisher
- BioMed Central (BMC)
- external identifiers
-
- wos:000254877100001
- scopus:42349098792
- pmid:18371232
- ISSN
- 1471-2407
- DOI
- 10.1186/1471-2407-8-81
- language
- English
- LU publication?
- yes
- additional info
- Department affilation moved from v1000588 (Tumour Biology, Malmö) to v1000562 (Department of Translational Medicine) on 2016-01-18 14:39:25.
- id
- e52264ac-7c30-4b93-b585-2e38849eaf8e (old id 1207346)
- date added to LUP
- 2016-04-01 13:46:09
- date last changed
- 2022-01-27 20:59:28
@article{e52264ac-7c30-4b93-b585-2e38849eaf8e,
abstract = {{Background: Metastatic prostate cancer is associated with a high morbidity and mortality but the spreading mechanisms are still poorly understood. The aminobisphosphonate alendronate, used to reduce bone loss, has also been shown to inhibit the invasion and migration of prostate cancer cells in vitro. We used a modified orthotopic PC-3 nude mouse tumor model of human prostate cancer to study whether alendronate affects prostate tumor growth and metastasis. Methods: PC-3 cells ( 5 x 105) were implanted in the prostates of nude mice and the mice were treated with alendronate ( 0.5 mg/kg/day in PBS, s.c.) or vehicle for 4 weeks. After sacrifice, the sizes of tumor-bearing prostates were measured and the tumors and prostate-draining regional iliac and sacral lymph nodes were excised for studies on markers of proliferation, apoptosis, angiogenesis and lymphangiogenesis, using histomorphometry and immunohistochemistry. Results: Tumor occurrence in the prostate was 73% in the alendronate-treated group and 81% in the control group. Mean tumor size ( 218 mm(3), range: 96-485 mm(3), n = 11) in the alendronate-treated mice was 41% of that in the control mice ( 513 mm(3), range: 209 - 1350 mm(3), n = 13) ( p < 0.05). In the iliac and sacral lymph nodes of alendronate-treated mice, the proportion of metastatic area was only about 10% of that in control mice ( p < 0.001). Immunohistochemical staining of tumor sections showed that alendronate treatment caused a marked decrease in the number of CD34-positive endothelial cells in tumors ( p < 0.001) and an increase in that of ISEL positive apoptotic cells in tumors as well as in lymph node metastases ( p < 0.05) compared with those in the vehicle-treated mice. The density of m-LYVE-I-stained lymphatic capillaries was not changed. Conclusion: Our results demonstrate that alendronate treatment opposes growth of orthotopic PC-3 tumors and decreases tumor metastasis to prostate-draining lymph nodes. This effect could be at least partly explained by decreased angiogenesis and increased apoptosis. The results suggest that bisphosphonates have anti-tumoral and anti-invasive effects on primary prostate cancer.}},
author = {{Tuomela, Johanna M. and Valta, Maija P. and Vaananen, Kalervo and Härkönen, Pirkko}},
issn = {{1471-2407}},
language = {{eng}},
publisher = {{BioMed Central (BMC)}},
series = {{BMC Cancer}},
title = {{Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice}},
url = {{http://dx.doi.org/10.1186/1471-2407-8-81}},
doi = {{10.1186/1471-2407-8-81}},
volume = {{8}},
year = {{2008}},
}